

**Colorectal Cancer (CRC) (update) Committee meeting 4**

**Date:** 03 May 2018

**Location:** RCOG, London

**Minutes:** Confirmed

<b>Committee members present:</b>		
Peter Hoskin, Chair <b>(PH)</b>		(Present for notes 1–8)
Justin Davies <b>(JD)</b>		(Present for notes 1–6)
Baljit Singh <b>(BS)</b>		(Present for notes 1–8)
Julie Hepburn <b>(JH)</b>		(Present for notes 1–8)
Debby Lennard <b>(DL)</b>		(Present for notes 1–8)
Vivek Misra <b>(VM)</b>		(Present for notes 1–8)
Charlotte Dawson <b>(CD)</b>		(Present for notes 1–8)
Michael Braun <b>(MB)</b>		(Present for notes 1–8)
Jay Bradbury <b>(JB)</b>		(Present for notes 1–8)
Richard Roope <b>(RR)</b>		(Present for notes 1–8)
Cindy Chew <b>(CC)</b>		(Present for notes 1–8)
Kevin Monahan <b>(KM)</b>		(Present for notes 1–8)
Richard Roope <b>(RR)</b>		(Present for notes 1–8)

<b>In attendance:</b>		
Justine Karpusheff <b>(JK)</b>	<b>NICE Guideline Commissioning Manager</b>	(Present for notes 1–6)
Lisa Boardman <b>(LB)</b>	NGA Guideline Lead	(Present for notes 1–8)
Matthew Prettyjohns <b>(MP)</b>	NGA Senior Health Economist	(Present for notes 1–8)
Michaela Dijmarescu <b>(MD)</b>	NGA Project Manager	(Present for notes 1–8)
Maija Kalioinen <b>(MK)</b>	NGA Systematic Reviewer	(Present for notes 1–8)
Nathan Bromham <b>(NB)</b>	NGA Senior Systematic Reviewer	(Present for notes 1–8)
Audrey Tan <b>(AT)</b>	NGA Systematic Reviewer	(Present for notes 1–8)
Agnesa Mehmeti <b>(JG)</b>	NGA Information Scientist	(Present for notes 4–8)

<b>Observers:</b>	
Ted Barker	NGA Systematic Reviewer
Maria Olsen	PhD Student (NICE Intern)

<b>Apologies:</b>	
Stephen Fenwick (SF)	Co-opted member

<b>1. Welcome, housekeeping, aims of the day and apologies</b>				
<p>The Chair welcomed the committee members to the 5th committee meeting for the colorectal cancer guideline (update).</p> <p>The Chair informed the committee that apologies had been received as noted above.</p> <p>The Chair outlined the objectives of the meeting, which included:</p> <ul style="list-style-type: none"> <li>• Presentations of evidence for <b>review questions 3.5</b> (Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?) and <b>3.6</b> (What is the optimal surgical technique for rectal cancer?);</li> <li>• Protocols signed off by the committee: <ul style="list-style-type: none"> <li>○ <b>Protocol 4.3.c</b> – What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?</li> <li>○ <b>Protocol 6.1</b> – Is there a relationship between surgical volumes and outcomes in the treatment of rectal cancer (primary and recurrent disease)?</li> <li>○ <b>Protocol 3.3</b> – Which people with non-metastatic colon cancer would benefit from preoperative chemotherapy?</li> </ul> </li> </ul> <p>The minutes of the 4th colorectal cancer guideline committee meeting were confirmed with the Committee.</p> <p>The Chair led round the table introductions for the group. The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.</p> <p>The Chair asked everyone to verbally declare any interests. The Chair made a note about the participation of committee members who have declared private practice.</p> <p>There were declarations of interest included in the table below.</p>				
<b>Name</b>	<b>Job title,</b>	<b>Declarations of</b>	<b>Type of</b>	<b>Decision taken</b>

	<b>organisation</b>	<b>Interest</b>	<b>interest</b>	
Debby Lennard	Lay member	Lay member on the research for NIHR Public Benefit Social Care Board. Role started in May 2018.  [03.05.2018]	Personal, non-financial, non-specific  *expenses and honorarium paid.	Declare and participate
Vivek Misra	Consultant Clinical Oncologist, Christie Hospital, Manchester	SI for OPERA trial in early rectal cancer  [03.05.2018]	Non-personal, non-financial, specific	Declare and participate
Richard Roope	G.P. $\frac{3}{4}$ - time Principal, The Whiteley Surgery, Whiteley	Invited to join the Clinical Advisory Panel at Cancer Research UK. Role started in May 2018.  [03.05.2018]	Personal, non-financial, specific  *expenses paid.	Declare and participate
Cindy Chew	Consultant Radiologist, Hairmyres Hospital, Glasgow	Local PI – TRIGGER Using the magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify between good and poor responders following chemoradiotherapy in rectal cancer: a multicentre randomised control trial  [01.05.2018]	Non-personal, financial, specific	Declare and participate
Michael Braun	Consultant Medical Oncologist	Attending the European Society of Medical Oncology 2018 meeting supported by Servier. Servier will provide flights, accommodation and conference registration fees, no direct or paid work involved.	Personal, non-financial, non-specific	Declare and participate

		[23.04.2018]		
Baljit Singh	Consultant Colorectal Surgeon and Honorary Senior Lecturer, Leicester General Hospital, Leicester	Clinical advisor role for NICE appraisal of darvadstrocel for treating complex perianal fistula in Crohn's disease. Role offered on the 25 <sup>th</sup> April 2018.  [09.05.2018]	Personal, non-financial, non-specific	Declare and participate
<b>2. Review 3.6 What is the optimal surgical technique for rectal cancer?</b>				
The Chair introduced Maija Kallionen (NGA Systematic Reviewer) who presented the evidence review for question 3.6 and the initial conclusions from the clinical evidence and took questions from the committee.				
<b>3. Review 3.6 What is the optimal surgical technique for rectal cancer?</b>				
The Chair introduced Matthew Prettyjohns (NGA Senior Health Economist) who presented the early stages of the economic model development for review question 3.6 and took questions from the committee.				
<b>4. Develop protocol for review question 4.3.c What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?</b>				
The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the protocol for review question 4.3 c and finalised it with the committee.				
<b>5. Develop protocol for review question 6.1 Is there a relationship between surgical volumes and outcomes in the treatment of rectal cancer (primary and recurrent disease)?</b>				
The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the protocol for review question 6.1 and finalised it with the committee.				
<b>6. Review 3.5 Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</b>				
The Chair introduced Nathan Bromham (NGA Senior Systematic Reviewer) who presented the evidence review for question 3.5 and the initial conclusions from the clinical evidence and took questions from the committee.  The Chair discussed the evidence with the committee and drafted recommendations.				
<b>7. Develop protocol for review question 3.3 Which people with non-metastatic colon cancer would benefit from preoperative chemotherapy?</b>				

The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the protocol for review question 3.3 and finalised it with the Committee.

**9. Any other business**

No other business was discussed.

**10. Close of meeting**

The Chair thanked the Committee and reminded them that the next meeting would be held on the 11<sup>th</sup> June 2018 at the RCOG, London and closed the 5th guideline committee meeting for the NICE Colorectal Cancer (update) guideline.

**Date of next meeting:** 11<sup>th</sup> June 2018

**Location of next meeting:** RCOG, London